Scarica l'app Stockscreener
219.88
1.32%
-2.94
Dopo l'orario di chiusura:
219.10
-0.78
-0.35%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$222.82
Aprire:
$222.98
Volume 24 ore:
779.64K
Relative Volume:
0.72
Capitalizzazione di mercato:
$32.49B
Reddito:
$9.60B
Utile/perdita netta:
$1.37B
Rapporto P/E:
23.60
EPS:
9.3182
Flusso di cassa netto:
$2.32B
1 W Prestazione:
-3.39%
1M Prestazione:
-1.25%
6M Prestazione:
+23.99%
1 anno Prestazione:
+41.63%
Intervallo 1D:
$219.81
$224.08
Intervallo di 1 settimana:
$219.81
$230.49
Portata 52W:
$138.00
$230.49
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
219.88 | 33.63B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,142.85 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.03 | 623.34B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
262.82 | 459.33B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
144.30 | 354.80B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
141.00 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-22 | Aggiornamento | UBS | Neutral → Buy |
| 2026-04-20 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | Iniziato | Barclays | Equal Weight |
| 2026-02-09 | Reiterato | H.C. Wainwright | Buy |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-10 | Downgrade | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Aggiornamento | Stifel | Hold → Buy |
| 2025-09-25 | Iniziato | Jefferies | Buy |
| 2025-07-21 | Ripresa | Truist | Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-04-04 | Downgrade | Argus | Buy → Hold |
| 2025-02-11 | Iniziato | Bernstein | Mkt Perform |
| 2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Downgrade | Stifel | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-11-18 | Downgrade | Needham | Buy → Hold |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-14 | Reiterato | Needham | Buy |
| 2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-24 | Reiterato | UBS | Buy |
| 2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-07 | Aggiornamento | Argus | Hold → Buy |
| 2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Downgrade | Stifel | Buy → Hold |
| 2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Reiterato | Barclays | Equal Weight |
| 2022-02-04 | Reiterato | BofA Securities | Neutral |
| 2022-02-04 | Reiterato | Cowen | Outperform |
| 2022-02-04 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-04 | Reiterato | Needham | Buy |
| 2022-02-04 | Reiterato | Oppenheimer | Outperform |
| 2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Reiterato | Robert W. Baird | Neutral |
| 2022-02-04 | Reiterato | Wedbush | Neutral |
| 2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
| 2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
| 2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Reiterato | Truist | Buy |
| 2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Reiterato | Barclays | Equal Weight |
| 2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-08 | Reiterato | Jefferies | Buy |
| 2021-06-08 | Reiterato | Morgan Stanley | Overweight |
| 2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Reiterato | Stifel | Buy |
| 2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
| 2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
| 2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
| 2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
How At Home Alzheimer’s Treatment Could Impact Biogen (BIIB) Investors - Simply Wall Street
How Biogen Inc. (BIIB) Affects Rotational Strategy Timing - Stock Traders Daily
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs? - Zacks Investment Research
Biogen stock closes 0.55 percent higher as Q2 growth holds - AD HOC NEWS
Biogen (BIIB) Could Be 4% Undervalued After Strong Earnings And Product News - simplywall.st
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack - Yahoo Finance
Biogen stock slips before the bell after September 24 close - AD HOC NEWS
Biogen stock trades near its 52-week high on growth bets - AD HOC NEWS
Biogen stock adds 3.40 percent ahead of the open - AD HOC NEWS
Biogen Inc. (BIIB) Options ChainYahoo Finance - Yahoo! Finance Canada
Biogen Inc. stock reaches a new 52-week high - AD HOC NEWS
Biogen stock heads into the open after a 2.7 percent gain - AD HOC NEWS
Biogen stock hits 52-week high at 225.88 USD By Investing.com - Investing.com Australia
Biogen stock hits 52-week high at 225.88 USD - Investing.com
Biogen stock slips after a lower close and analyst notes - AD HOC NEWS
Biogen stock heads into the open after a 1.6 percent decline - AD HOC NEWS
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Learn Why The Bull Case For Biogen Stock Could Change Following At Home LEQEMBI Approval - simplywall.st
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day - Zacks Investment Research
Biogen Inc. stock holds near top of 52-week range after EMPAVELI data update - AD HOC NEWS
Biogen stock heads into the open after a 1.6 percent slide - ad-hoc-news.de
Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Size, Share & Growth Report, 2035 - SNS Insider
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook - The Motley Fool
Biogen Inc. stock reacts to Leqembi Pen approval and fresh guidance - AD HOC NEWS
Biogen acquires RayThera Inc. (August 2026) - app.dealroom.co
Biogen Inc. stock gains regulatory boost from Japan approval for Leqembi Pen - AD HOC NEWS
Biogen Inc. stock gains after new EMPAVELI kidney data publication - AD HOC NEWS
Biogen Inc. stock trades near 52-week high as analysts keep a Moderate Buy stance - AD HOC NEWS
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN - Biogen
Biogen: Growth Is Back, But It Came At A Price (NASDAQ:BIIB) - Seeking Alpha
Biogen Announces Published VALIANT Data Showing EMPAVELI Reduced Proteinuria in Adolescents with C3G and Primary IC-MPGN - Quiver Quantitative
Is Biogen Stock Outperforming the S&P 500? - finance.yahoo.com
Eisai and Biogen Announce Japan Approval of LEQEMBI Pen, a Once-Weekly Subcutaneous Alzheimer’s Treatment - Quiver Quantitative
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease - Yahoo Finance
Biogen (BIIB) Wins China Approval For At Home Weekly Alzheimer’s Treatment - simplywall.st
Biogen to Report Third Quarter 2026 Financial Results October 28, 2026 - Biogen
Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades—Which Pharma Stock Has More Upside? - Yahoo Finance
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience - Yahoo Finance
Biogen Inc. at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Biogen Inc. (BIIB) Stock Analysis: Exploring a 9.23% Potential Upside with Strategic Collaborations - DirectorsTalk Interviews
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology - TradingView
Biogen (BIIB) Sees Canada Back LEQEMBI As Fair Value Stays In Focus - simplywall.st
Alzheimer’s Disease Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Alpha Cognition, Biogen, Eisai, Eli Lilly, Otsuka Pharma, Lundbeck, Suven Life Sciences, Roche - Barchart.com
Multiple Sclerosis Market Outlook 2036: Growth Trends, Competitive Landscape, and Future Opportunities by 2034 – DelveInsight | Biogen, Immune Response BioPharma, ImCyse, Atara Bio, Emerald Health - Barchart.com
BIIB Maintained by HSBC -- Price Target Raised to $175 - GuruFocus
Biogen Inc. stock gains on fresh analyst upgrades and strong Q2 figures - ad-hoc-news.de
Stifel reiterates Biogen stock rating on immunology pipeline - investing.com
Stifel reiterates Biogen stock rating on immunology pipeline By Investing.com - Investing.com Canada
Can Biogen (NASDAQ:BIIB) Stay Resilient As Inflation Rises? - Kalkine Media
Biogen Inc. (BIIB) Stock Forecasts - Yahoo Finance
Biogen at Wells Fargo healthcare conference: growth bets widen By Investing.com - Investing.com Canada
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Biogen Inc Azioni (BIIB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Minor Lloyd | Director |
Aug 04 '26 |
Sale |
200.96 |
593 |
119,169 |
2,689 |
1.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):